Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted MiR-150 Nanoparticles
Overview
Authors
Affiliations
Acute myeloid leukemia (AML) is a common and fatal form of hematopoietic malignancy. Overexpression and/or mutations of FLT3 have been shown to occur in the majority of cases of AML. Our analysis of a large-scale AML patient cohort (N = 562) indicates that FLT3 is particularly highly expressed in some subtypes of AML, such as AML with t(11q23)/MLL-rearrangements or FLT3-ITD. Such AML subtypes are known to be associated with unfavorable prognosis. To treat FLT3-overexpressing AML, we developed a novel targeted nanoparticle system: FLT3 ligand (FLT3L)-conjugated G7 poly(amidoamine) (PAMAM) nanosized dendriplex encapsulating miR-150, a pivotal tumor suppressor and negative regulator of FLT3 We show that the FLT3L-guided miR-150 nanoparticles selectively and efficiently target FLT3-overexpressing AML cells and significantly inhibit viability/growth and promote apoptosis of the AML cells. Our proof-of-concept animal model studies demonstrate that the FLT3L-guided miR-150 nanoparticles tend to concentrate in bone marrow, and significantly inhibit progression of FLT3-overexpressing AML in vivo, while exhibiting no obvious side effects on normal hematopoiesis. Collectively, we have developed a novel targeted therapeutic strategy, using FLT3L-guided miR-150-based nanoparticles, to treat FLT3-overexpressing AML with high efficacy and minimal side effects. Cancer Res; 76(15); 4470-80. ©2016 AACR.
Antisense oligonucleotides as a targeted therapeutic approach in model of acute myeloid leukemia.
Maceckova D, Vankova L, Bufka J, Hosek P, Moravec J, Pitule P Mol Biol Rep. 2024; 52(1):57.
PMID: 39692897 DOI: 10.1007/s11033-024-10172-w.
Recent Advances in miRNA-Based Therapy for MASLD/MASH and MASH-Associated HCC.
Carpi S, Daniele S, de Almeida J, Gabbia D Int J Mol Sci. 2024; 25(22).
PMID: 39596297 PMC: 11595301. DOI: 10.3390/ijms252212229.
Current advance of nanotechnology in diagnosis and treatment for malignant tumors.
Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y Signal Transduct Target Ther. 2024; 9(1):200.
PMID: 39128942 PMC: 11323968. DOI: 10.1038/s41392-024-01889-y.
Qiu Y, Bai L, Zhao H, Mei X BMC Cancer. 2024; 24(1):520.
PMID: 38658865 PMC: 11044605. DOI: 10.1186/s12885-024-12286-7.
Ashoub M, Razavi R, Heydaryan K, Salavati-Niasari M, Amiri M Eur J Med Res. 2024; 29(1):224.
PMID: 38594732 PMC: 11003188. DOI: 10.1186/s40001-024-01822-7.